Collectively, these ten firms generated total revenues of $1.74 billion. By itself, Roche Diagnostics represents 40% of this market. One reason for this large number is the revenues generated by the PCR patents the company owns.
As can be seen, six of the companies on this list are selling less than $100 million per year in the clinical molecular diagnostics market. This demonstrates the relatively small volumes of clinical testing conducted using molecular technologies.
However, growth rates in this market segment are in double digits. Because of the compound effects of such growth rates, the ratio of clinical molecular testing performed will increase steadily.
Further, the research and development pipeline is full of new markers and new molecular technologies. Each year, the laboratory industry can expect to see more molecular assays enter the clinical marketplace. This ranking for 2004 will provide pathologists and laboratory directors with a baseline from which to evaluate future growth in clinical molecular testing.